Trial Profile
A Feasibility and Biomarker Study to Evaluate Necitumumab in the Neoadjuvant Setting With Gemcitabine and Cisplatin in Surgically Resectable Squamous Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2020
Price :
$35
*
At a glance
- Drugs Necitumumab (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 05 Feb 2020 Status changed from completed to discontinued.
- 10 Dec 2019 Status changed from recruiting to completed.
- 05 Jul 2018 New trial record